Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neurocrine Biosciences Inc NBIX

Healthcare Biotechnology
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington... see more

Recent & Breaking News (NDAQ:NBIX)

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

PR Newswire 4 days ago

Neurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

PR Newswire 9 days ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

PR Newswire 9 days ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

PR Newswire 10 days ago

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

PR Newswire 10 days ago

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst(TM) Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

PR Newswire 11 days ago

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

PR Newswire 12 days ago

Neurocrine Biosciences Presented CAHtalyst(TM) Pediatric Study Baseline Characteristics and CAHtalog(TM) Registry Data at PES 2024

PR Newswire May 3, 2024

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

PR Newswire May 1, 2024

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

PR Newswire April 30, 2024

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

PR Newswire April 24, 2024

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

PR Newswire April 23, 2024

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

PR Newswire April 10, 2024

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

PR Newswire April 3, 2024

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

PR Newswire March 28, 2024

Neurocrine Biosciences to Participate at Virtual Investor Conferences in March

PR Newswire March 11, 2024

Neurocrine Biosciences to Participate at Investor Conferences in March

PR Newswire February 27, 2024

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024

PR Newswire February 7, 2024

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results

PR Newswire January 17, 2024

Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 2, 2024